These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 24510515)

  • 101. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
    Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
    J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.
    Li H; Omange RW; Liang B; Toledo N; Hai Y; Liu LR; Schalk D; Crecente-Campo J; Dacoba TG; Lambe AB; Lim SY; Li L; Kashem MA; Wan Y; Correia-Pinto JF; Seaman MS; Liu XQ; Balshaw RF; Li Q; Schultz-Darken N; Alonso MJ; Plummer FA; Whitney JB; Luo M
    J Clin Invest; 2020 Dec; 130(12):6429-6442. PubMed ID: 32853182
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.
    Petitdemange C; Kasturi SP; Kozlowski PA; Nabi R; Quarnstrom CF; Reddy PBJ; Derdeyn CA; Spicer LM; Patel P; Legere T; Kovalenkov YO; Labranche CC; Villinger F; Tomai M; Vasilakos J; Haynes B; Kang CY; Gibbs JS; Yewdell JW; Barouch D; Wrammert J; Montefiori D; Hunter E; Amara RR; Masopust D; Pulendran B
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830870
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Live attenuated AIDS viruses as vaccines: promise or peril?
    Ruprecht RM
    Immunol Rev; 1999 Aug; 170():135-49. PubMed ID: 10566148
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.
    Demberg T; Robert-Guroff M
    Int Rev Immunol; 2009; 28(1):20-48. PubMed ID: 19241252
    [TBL] [Abstract][Full Text] [Related]  

  • 107.
    Fuller DH; O'Connor MA
    AIDS Res Hum Retroviruses; 2022 May; 38(5):347-349. PubMed ID: 35172614
    [No Abstract]   [Full Text] [Related]  

  • 108. Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.
    Ackerman ME; Das J; Pittala S; Broge T; Linde C; Suscovich TJ; Brown EP; Bradley T; Natarajan H; Lin S; Sassic JK; O'Keefe S; Mehta N; Goodman D; Sips M; Weiner JA; Tomaras GD; Haynes BF; Lauffenburger DA; Bailey-Kellogg C; Roederer M; Alter G
    Nat Med; 2018 Oct; 24(10):1590-1598. PubMed ID: 30177821
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Old world monkeys and new age science: the evolution of nonhuman primate systems virology.
    Palermo RE; Tisoncik-Go J; Korth MJ; Katze MG
    ILAR J; 2013; 54(2):166-80. PubMed ID: 24174440
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.
    Klasse PJ; Moore JP
    J Virol; 2022 Apr; 96(8):e0003422. PubMed ID: 35384694
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Challenges in mucosal HIV vaccine development: lessons from non-human primate models.
    Tuero I; Robert-Guroff M
    Viruses; 2014 Aug; 6(8):3129-58. PubMed ID: 25196380
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies.
    Irvine C; Egan KJ; Shubber Z; Van Rompay KK; Beanland RL; Ford N
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S165-9. PubMed ID: 25972498
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Microbiome Studies in Non-human Primates.
    Brenchley JM; Ortiz AM
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):527-537. PubMed ID: 34735686
    [TBL] [Abstract][Full Text] [Related]  

  • 114. HIV vaccine candidate plus microbicide decreases SIV infection risk by more than 90.
    Nat Microbiol; 2023 May; 8(5):767-768. PubMed ID: 37024619
    [No Abstract]   [Full Text] [Related]  

  • 115. The impact of MDSCs on the efficacy of preventive and therapeutic HIV vaccines.
    Yaseen MM; Abuharfeil NM; Darmani H
    Cell Immunol; 2021 Nov; 369():104440. PubMed ID: 34560382
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The role of Fc receptors in HIV infection and vaccine efficacy.
    Cocklin SL; Schmitz JE
    Curr Opin HIV AIDS; 2014 May; 9(3):257-62. PubMed ID: 24670320
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Clinical development of candidate HIV vaccines: different problems for different vaccines.
    Shapiro SZ
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):325-9. PubMed ID: 24168166
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Quantitative MRI Measures in SIV-Infected Macaque Brains.
    Zhang X; Li C
    J Clin Cell Immunol; 2013; Suppl 7():. PubMed ID: 24244892
    [TBL] [Abstract][Full Text] [Related]  

  • 119. The mechanistic analysis of founder virus data in challenge models.
    Ortega-Villa AM; Nason MC; Follmann D
    Stat Med; 2021 Sep; 40(20):4492-4504. PubMed ID: 34111904
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Genomic Evidence for the Nonpathogenic State in HIV-1-Infected Northern Pig-Tailed Macaques.
    Pang W; Shao Y; Zhuang XL; Lu Y; He WQ; Zheng HY; Xin R; Zhang MX; Zhang XL; Song JH; Tian RR; Shen F; Li YH; Zhao ZJ; Wu DD; Zheng YT
    Mol Biol Evol; 2023 May; 40(5):. PubMed ID: 37134013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.